Haemolytic uraemic syndrome (HUS) is
Introduction
Haemolytic uraemic syndrome (HUS) is characterized by thrombotic lesions in various organs, producing microangiopathic haemolytic anaemia and thrombocytopenia, and resulting in a clinical spectrum varying from renal failure to multiple organ dysfunction. 1,2 Calcineurin inhibitors have frequently been incriminated and reports of over 20 cases of tacrolimusassociated HUS have been published, 3,4 three of which occurred following liver transplantation. 5 -7 Small-for-size syndrome is a complication of living-donor liver transplantation and is characterized by delayed graft function, resulting in metabolic disturbance. To the authors' knowledge this report describes the first case of tacrolimus-associated HUS in a woman with small-for-size syndrome after livingdonor liver transplantation.
Case report
A 57-year-old woman underwent orthotopic liver transplantation for autoimmune hepatitis that had been diagnosed 3 years previously. For the first 2 years, the disease was under control without treatment, but liver failure and portal hypertension later ensued. Two months prior to transplantation, Y Luo, A Zhang, H Huang et al.
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the woman was admitted to hospital for oesophageal variceal bleeding. Varices were banded and intravenous octreotide and pantoprazole were administered. The diagnosis of autoimmune hepatitis was once again confirmed by the presence of positive autoantibodies, including antinuclear antibodies, smooth muscle antibodies and anti-mitochondrial antibodies, and negative serological markers of the hepatitis A, B and C viruses.
The patient then underwent living-related liver transplantation with an ABO compatible graft. Before operation, the liver of the donor was evaluated by MeVis study, which enables three-dimensional computed tomography volumetry and calculation of the regional volume of each drainage vein in the liver. CT and MRI images showed no abnormality of the biliary duct or blood vessels in the liver. The volumes of the right and left lobes were 656 and 368 ml, respectively. According to the criterion of a graft-to-body weight ratio ≥ 0.8% to prevent post-operative graft dysfunction, the left liver lobe of the donor was theoretically large enough for a patient of this size (the patient weighed 36 kg). During the operation, the left lobe and its middle hepatic vein were successfully excised and grafted. The grafted lobe weighed 256 g and the explanted liver weighed 520 g. The graft-to-recipient weight ratio was 0.7% and the ratio of the graft volume and standard liver volume was nearly 50%, which was a critical value. Histological examination of the explanted liver confirmed autoimmune hepatitis.
Post-operatively, prophylactic antibiotic treatment was initiated with moxifloxacin. Prophylactic antifungal and anticytomegalovirus therapy was added with fluconazole and ganciclovir, respectively. Mycophenolate mofetil and methylprednisolone were given routinely as antirejection agents. Since basiliximab had been used during the operation, tacrolimus was then given at a dose of 0.05 mg/kg body weight (1 mg every 12 h) from the third postoperative day. Plasma tacrolimus concentration was monitored daily and it attained a steady-state of 20 ng/ml on the sixth post-operative day. The dose was then reduced to half and, the next day, it was found to be at a plasma concentration >30 ng/ml and was withdrawn.
Liver function was abnormal at all times post-operatively, evidenced by elevated alanine transaminase and total bilirubin levels, and prolonged prothrombin times. Refractory ascites developed as the daily ascite output was 600 -1000 ml in the absence of vascular complications. A search for Escherichia coli O157:H7 was negative in peritoneal cultures taken routinely at the time of laparotomy and after operation. Bscan ultrasound examination suggested portal hypertension, with evidence of portal blood flow velocity of 80 -100 cm/s. Biopsy of the graft showed marked cholestasis, centrilobular sinusoidal dilatation and hepatocyte atrophy, therefore establishing the diagnosis of small-for-size syndrome.
Six days after transplantation, the patient developed hypertension, which was poorly controlled with nifedipine. Serum creatinine concentration increased and platelet count and haemoglobin levels dropped (Fig. 1) . The platelet count and haemoglobin dropped again even after infusion of concentrated platelets and red cells. On post-operative day 7, the haemolytic nature of the anaemia was confirmed by an unconjugated bilirubin concentration of 113 µmol/l (normal < 17 µmol/l), a lactate dehydrogenase level of 3121 IU/l (normal 380 -770 IU/l), a characteristic blood smear and a haptoglobin level of 0.1 mg/l (normal 0.32 -1.98 mg/l). Serum creatinine increased Y Luo, A Zhang, H Huang et al. HUS after liver transplantation dramatically ( Fig. 1) and erythrocyte casts appeared in the urine. Daily urine output decreased to < 500 ml. HUS was diagnosed based on these results. Daily plasmapheresis was initiated and intravenous immunoglobulin and methylprednisolone were later added. The patient, however, did not respond to this therapy and HUS continued to worsen, with steadily increasing serum creatinine and decreasing hourly urine output. On post-operative day 9, multiple organ failure developed, defined as no urine, decreased blood pressure with no response to dopamine therapy, and no portal inflow evidenced by emergency B-scan ultrasounds. The patient died of multiple organ failure.
Discussion
This is the first report of tacrolimusassociated HUS in a woman with small-forsize syndrome after living-donor liver transplantation. In retrospect, the features of HUS were present 1 day before appropriate treatment was initiated. Overlap of symptoms of HUS with other complications of liver transplantation posed a diagnostic challenge in the immediate post-transplant period.
Post-transplant HUS has been reported with increasing frequency and appears to affect a progressively increasing number of patients worldwide. 8 Although the pathogenesis of HUS is poorly understood, activation of microvascular endothelium is believed to play a central role in its development. 1 This activation eventually leads to endothelium-blood interaction and platelet thrombosis (thrombotic microangiopathy) of target organs and secondary organ failure.
Multiple factors have been implicated in the development of post-transplant HUS, including immunosuppressive agents and systemic viral infections, particularly cytomegalovirus. The immunosuppressive medications that have been documented to be associated with HUS development include cyclosporin, tacrolimus and OKT-3. Over 20 cases of tacrolimus-induced HUS have been 
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reported, with an incidence of approximately 1%, which is probably comparable with the incidence related to cyclosporin A.
9
Tacrolimus heightens renal vascular resistance by increasing endothelin-1 and thromboxane A2, and inhibiting nitric oxide synthase activation, favouring vasoconstriction, platelet aggregation and microthrombosis, and may have an independent role in inducing HUS. 10 -13 Cytomegalovirus has also been reported as being involving in the pathogenesis of transplant-associated HUS. 14 It can infect endothelial cells through specific binding to a P-antigen on the cell surface, which can sustain platelet adhesion to the microvascular wall by inducing the expression of adhesion molecules and the release of von Willebrand factor. Murer et al. 15 reported four cases of biopsy-proven HUS occurring after renal transplantation triggered by parvovirus B19 infection, with similar mechanisms to those involving cytomegalovirus. Our patient was negative for serum cytomegalovirus and Epstein-Barr virus, and parvovirus B19 DNA was also not detected by quantitative polymerase chain reaction.
Several other risk factors have been reported as potential inducers of HUS. For example a slight defect in the factor H gene in donor liver has been reported to increase the potential toxic effect of tacrolimus. 16, 17 The decreased factor H levels failed properly to restrict complement deposition that had been initiated by several factors, such as infection and the effect of cytotoxic drugs on endothelial cells, and led to microvasculature cell membrane and tissue destruction. The serum factor H level in our reported case was normal and the factor H genotype, assessed by fluorescence sequencing, detected no mutation. Thus, the association between tacrolimus and HUS was proposed in our case. The relationship between tacrolimus concentration and the incidence of HUS is not well established. In those cases that have been reported, the dose of tacrolimus varied from 0.03 mg/kg by the intravenous route to 14 mg/day orally, and trough levels were within the therapeutic range, with the exception of one case whose level of tacrolimus was as high as 52.5 ng/ml. 3 In our patient, a concentration of > 30 ng/ml was believed to contribute to poor early graft functioning and to be an independent risk factor for the development of HUS.
Use of small-for-size grafts is a major causative factor of impaired post-operative graft function. Poor early graft function is characterized by protracted cholestasis and disturbance of metabolism. A graft-torecipient weight ratio of 0.8%, and preferably 1.0%, and a ratio of graft volume to standard liver volume (GV/SV ratio) of 50% has been recommended to prevent postoperative graft dysfunction. 18 -20 In the case of our patient, the graft-to-recipient weight ratio was 0.7% and the GV/SV ratio was nearly 50%. We diagnosed small-for-size syndrome based on clinical presentation and liver biopsy.
Clinical and experimental studies of the pharmacokinetics of tacrolimus in small-forsize grafts have indicated that its serum concentration is related to the size of the liver graft. 21, 22 Kishino et al. 23 reported that interand intra-individual variations in hepatic cytochrome P450 (CYP) 3A4 activity were caused by differences in the GV/SV ratio. They also demonstrated that graft size (GV/SV ratio) could cause inter-individual variations in the half-life time of tacrolimus in the immediate post-operative period. Fukatsu et al. 24 reported that the weight of the hepatic graft was significantly correlated with clearance of tacrolimus in adult Y Luo, A Zhang, H Huang et al.
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patients who had undergone living-donor liver transplant. Sugawara et al. 25 reported that the optimum tacrolimus dose was best correlated with the GV/SV ratio and that the dose of tacrolimus in the immediate postoperative period can be estimated from equations using the GV/SV ratio. In addition, Trotter et al. 26 reported that recipients of living-donor liver transplants achieved higher serum levels of immunosuppressive agents than recipients of cadaveric donor transplants given the same dose. These results suggest that graft size (GV/SV ratio) is important and could give rise to intraindividual variations in the optimal dosage. On the other hand, genetic polymorphisms in drug-metabolizing enzymes have been linked to interindividual differences in the efficacy and toxicity of many medications. Tacrolimus is mainly metabolized by CYP3A5, which is the major phase I drug-metabolizing enzyme in the liver. 27 -29 We previously demonstrated a significant association between the tacrolimus blood concentration:dose ratio and the donor CYP3A5 genotype in liver transplantation. 30 The CYP3A5 polymorphism genotypes of the donor and recipient were, therefore, analysed retrospectively and showed that both were heterozygous for the *3 allele, which correlates with high gene expression and enzyme activity. Thus, a possible association between the donor CYP3A5 genotype and tacrolimus blood concentration was eliminated. It is predicable that the notably increased tacrolimus blood concentration contributed to a small-for-size graft in the present case.
In conclusion, the case described illustrates a possible association between the incidence of HUS and a high concentration of tacrolimus due to small-for-size syndrome. It would, therefore, be prudent to use a low dose of tacrolimus in recipients with smallfor-size grafts, in order to compensate for the potentially increased blood concentrations of tacrolimus that might occur compared with the whole-liver state. The tacrolimus concentration in the blood should be carefully monitored after treatment is initiated, and any sudden increase requires immediate drug withdrawal to avoid toxic levels being reached.
